BD Diagnostics TriPath

BD TriPath is a specialized diagnostic unit within Becton, Dickinson and Company (BD) that focuses on advanced solutions for cancer screening and women's health. Formed through the acquisition of TriPath Imaging in 2006, the company is a global leader in liquid-based cytology and automated imaging technologies. Its core portfolio includes the BD SurePath Liquid-Based Pap Test and the BD FocalPoint Slide Profiler, which are designed to improve the detection of cervical cancer and its precursors. Additionally, BD TriPath offers molecular diagnostic adjuncts like the ProEx C assay, which utilizes biomarkers to assist in identifying high-grade cervical disease. The company's integrated systems streamline laboratory workflows from specimen collection to automated analysis, enhancing diagnostic accuracy and patient care.